KR101411272B1 - ＨＩＶ Ｖｉｆ 돌연변이체 - Google Patents

ＨＩＶ Ｖｉｆ 돌연변이체 Download PDF

Info

Publication number
KR101411272B1
KR101411272B1 KR1020077022937A KR20077022937A KR101411272B1 KR 101411272 B1 KR101411272 B1 KR 101411272B1 KR 1020077022937 A KR1020077022937 A KR 1020077022937A KR 20077022937 A KR20077022937 A KR 20077022937A KR 101411272 B1 KR101411272 B1 KR 101411272B1
Authority
KR
South Korea
Prior art keywords
delete delete
leu
arg
lys
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077022937A
Other languages
English (en)
Korean (ko)
Other versions
KR20070118624A (ko
Inventor
치아라 보보렌타
Original Assignee
몰메드 에스피에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0504770A external-priority patent/GB0504770D0/en
Priority claimed from GB0510888A external-priority patent/GB0510888D0/en
Application filed by 몰메드 에스피에이 filed Critical 몰메드 에스피에이
Publication of KR20070118624A publication Critical patent/KR20070118624A/ko
Application granted granted Critical
Publication of KR101411272B1 publication Critical patent/KR101411272B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020077022937A 2005-03-08 2006-03-07 ＨＩＶ Ｖｉｆ 돌연변이체 Expired - Fee Related KR101411272B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0504770A GB0504770D0 (en) 2005-03-08 2005-03-08 HIV Vif
GB0504770.9 2005-03-08
GB0510888.1 2005-05-26
GB0510888A GB0510888D0 (en) 2005-05-26 2005-05-26 Hiv vif
PCT/IB2006/001519 WO2006111866A2 (en) 2005-03-08 2006-03-07 Hiv vif mutants

Publications (2)

Publication Number Publication Date
KR20070118624A KR20070118624A (ko) 2007-12-17
KR101411272B1 true KR101411272B1 (ko) 2014-07-03

Family

ID=37115522

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077022937A Expired - Fee Related KR101411272B1 (ko) 2005-03-08 2006-03-07 ＨＩＶ Ｖｉｆ 돌연변이체

Country Status (9)

Country Link
US (1) US8912152B2 (enExample)
EP (1) EP1883649B1 (enExample)
JP (1) JP5324912B2 (enExample)
KR (1) KR101411272B1 (enExample)
AT (1) ATE533777T1 (enExample)
AU (1) AU2006238617B2 (enExample)
CA (1) CA2599525C (enExample)
ES (1) ES2377829T3 (enExample)
WO (1) WO2006111866A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011015379A1 (en) 2009-08-05 2011-02-10 Nexigen Gbmh Human hcv-interacting proteins and methods of use
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
KR102458904B1 (ko) * 2020-06-19 2022-11-01 숙명여자대학교산학협력단 신규의 bmpr2 유전자 기능획득 돌연변이체 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198784B2 (en) * 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US7220554B2 (en) * 2003-05-23 2007-05-22 Oregon Health And Science University Methods for identifying inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, Vol. 72, pp. 4308-4319 (1998.03.) *
Journal of Virology, Vol. 73, pp. 2675-2681 (1999.04.) *
Virology, Vol. 194, pp. 441-452 (1993.06.) *

Also Published As

Publication number Publication date
ATE533777T1 (de) 2011-12-15
WO2006111866A2 (en) 2006-10-26
EP1883649B1 (en) 2011-11-16
JP2008532510A (ja) 2008-08-21
JP5324912B2 (ja) 2013-10-23
KR20070118624A (ko) 2007-12-17
AU2006238617B2 (en) 2012-08-02
CA2599525A1 (en) 2006-10-26
US20080286248A1 (en) 2008-11-20
WO2006111866A3 (en) 2007-04-12
CA2599525C (en) 2015-05-26
US8912152B2 (en) 2014-12-16
EP1883649A2 (en) 2008-02-06
AU2006238617A1 (en) 2006-10-26
ES2377829T3 (es) 2012-04-02

Similar Documents

Publication Publication Date Title
JP3613734B2 (ja) ヒト免疫不全ウィルスの新規トランスドミナントｔａｔ変異体
EP0791065A1 (en) Protein targeting into hiv virions based on hiv-1 vpr fusion molecules
KR101252065B1 (ko) 유전자 치료를 위한 벡터
WO1990011359A1 (en) Intracellular method of inhibiting hiv in mammalian cells
HERCHENRÖDER et al. Infectious proviral clones of chimpanzee foamy virus (SFVcpz) generated by long PCR reveal close functional relatedness to human foamy virus
KR101411272B1 (ko) ＨＩＶ Ｖｉｆ 돌연변이체
AU2003242496B2 (en) Conjugate
WO2012118092A1 (ja) 融合タンパク質
WO1998043669A1 (en) Chimeric viral proteins
CN101137666B (zh) HIV Vif突变体
US20110294219A1 (en) Use of the foamy virus bet protein for inactivating apobec
CA2155568A1 (fr) Vecteurs exprimant un interferon humain pour le traitement du sida
NZ333190A (en) Inhibition of HIV-1 replication by antisense RNA expression using transduced hematopoietic cells
WO2001070941A2 (en) An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
CA2372456C (en) Viral infection inhibitor targeting integrase n-terminal domain
WO2005077105A2 (en) Reduction of hiv-1 replication by a mutant apolipoprotein b mrna editing enzyme-catalytic polypeptide-like 3 g (apobec3g)
KR20020008406A (ko) 향상된 벡터를 선택하는 방법
WO2014092090A1 (ja) ウイルスベクター産生細胞及びベクターの製造方法
FR2713651A1 (fr) Nouvelle composition pour un effet antiviral.
WO1996037235A1 (en) Methods for inhibition of hiv

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170612

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180619

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180619

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000